Spectroscopic and Molecular Docking Studies of the *in Vitro* Interaction between Puerarin and Cytochrome P450

Jiangjuan Shao *, Jianwei Chen, Tingting Li and Xiaoli Zhao

College of Pharmacy, Nanjing University of Chinese Medicine, Xianlin Avenue No. 138, Nanjing 210023, China; E-Mails: chenjw695@126.com (J.C.); ttli734493813@163.com (T.L.); xlee_zhao@163.com (X.Z.)

* Author to whom correspondence should be addressed; E-Mail: shao.jiangjuan.cbfp@gmail.com or jjshao1976@163.com; Tel.: +86-25-8581-1520; Fax: +86-25-8581-1524.

Received: 7 February 2014; in revised form: 5 April 2014 / Accepted: 9 April 2014 / Published: 16 April 2014

**Abstract:** Puerarin, an isoflavone glycoside extracted from *Pueraria* plants, has various medical functions. Cytochrome P450s (CYPs) are crucial phase I metabolizing enzymes, which have been spotlighted for their effects on drug metabolism. The interaction between puerarin and CYPs (CYP1A2 and CYP2D6) was investigated by fluorescence, UV-Vis and circular dichroism spectroscopies, as well as molecular docking, to explore the underlying mechanism under simulated physiological conditions. The molecular docking results indicated that puerarin interacted with CYPs mainly by hydrophobic force and hydrogen bonding. The fluorescences of CYPs were quenched statically. Binding constants (Kₐ) and number of binding sites (n) at different temperatures were calculated, with the results being consistent with those of molecular docking. At the same temperature, puerarin bound to CYP1A2 more weakly than it did to CYP2D6. UV-Vis and circular dichroism spectroscopies confirmed the micro-environmental and conformational changes of CYP1A2 and CYP2D6. The findings provide reliable evidence for clarifying the structures and functions of CYPs.

**Keywords:** puerarin; cytochrome P450; spectroscopy; molecular docking

1. Introduction

Puerarin (4′,7-dihydroxy-8-β-D-glucose isoflavone), an isoflavone glycoside extracted from *Pueraria* plants, can lower blood pressure, resist oxidation, arrhythmia and inflammation, as well as inhibit tumor
cell proliferation [1–4]. Cytochrome P450s (CYPs), which are crucial phase I metabolizing enzymes, have been spotlighted for their effects on drug metabolism. Most drugs are detoxified via CYP-dependent pathways. Particularly, approximately 90% of drugs are metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 [5], which may be interrupted in case their activities are induced or inhibited [6].

Recently, the interactions between small molecules (puerarin herein) of Traditional Chinese Medicine (TCM) and biomacromolecules (CYPs herein) have been extensively studied [7,8]. Unraveling the interactions on the molecular level is conducive to understanding the pharmacological actions of drugs in vivo, as well as designing and screening novel drugs with lower toxicities and side effects. Wang et al. studied the effect of puerarin on different cytochrome P450 activities by probes. Their conclusions proved that puerarin had no significant effects on the activities of CYP2C9, CYP2C19 and CYP3A4, but remarkably inhibited the activity of CYP1A2 and CYP2D6 in a dose-dependent fashion [9]. Therefore, the interactions between them were investigated herein by fluorescence, UV-Vis and circular dichroism (CD) spectroscopies, as well as molecular docking, aiming to provide evidence for studying the understanding the interactions between CYPs, this and other drugs.

2. Results and Discussion

2.1. Fluorescence Spectroscopy

2.1.1. Quenching of CYPs Fluorescence by Puerarin

Tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe) residues in proteins have a fluorescence intensity ratio of 100:9:0.5. Therefore, protein fluorescence mainly originates from Trp residues, and by measuring it we can predict the conformational changes before and after interacting with drugs. In this study, the quenching of CYPs’ fluorescence by puerarin was studied when excited at 280 nm at 293 K or 303 K. The results are shown in Figure 1. Although the fluorescence intensity of CYP1A2 was higher than that of CYP2D6, they were both quenched by puerarin, accompanied by maximum emission shifts, suggesting puerarin bound to the two CYPs, quenched their endogenous fluorescences and altered the microenvironment of emitting groups.

**Figure 1.** Fluorescence spectra of CYPs in the presence of various concentrations of puerarin (T = 303 K, concentrations of puerarin (1→9): 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and $4 \times 10^{-5}$ mol L$^{-1}$). (A) puerarin-CYP1A2; (B) puerarin-CYP2D6.
2.1.2. Fluorescence Quenching Mechanism

Quenching refers to any process which decreases the fluorescence intensity of a given substance. A variety of processes, such as excited state reactions, energy transfer, complex formation and collisional quenching, can result in quenching. The fluorescence of protein is quenched by drug molecules both dynamically and statically, and the quenching efficiency follows the Stern–Volmer relationship [10]:

\[
\frac{F_0}{F} = 1 + K_q \tau_0 [Q] = 1 + K_{sv} [Q]
\]

where \( F_0 \) is the intensity without a quencher, \( F \) is the intensity with a quencher, \( K_q \) is the rate constant of bimolecular quenching, \( K_{sv} \) is the dynamic quenching constant, \( \tau_0 \) is the average lifetime of the emissive molecule without a quencher (biomacromolecules: \( 10^{-8} \) s), and \([Q]\) is the concentration of the quencher. Plotting \( F_0/F \) vs. \([Q]\) indicates the types of quenching, i.e., a straight line for individual static or dynamic quenching, and an upward curve for mixed types [11].

Figure 2 shows good linear relationships, with the slope decreasing with rising temperature. Meanwhile, the quenching parameters are listed in Table 1. For instance, the quenching rate constants of puerarin-CYP1A2 at 303 K and 293 K were \( 5.98 \times 10^{12} \) and \( 6.46 \times 10^{12} \) L⋅mol\(^{-1}\)⋅s\(^{-1}\) respectively, which were higher than the maximum diffusion constant of collisional quenching (\( 2 \times 10^{10} \) L⋅mol\(^{-1}\)⋅s\(^{-1}\)). Besides, the quenching rate constant reduced with increasing temperature, suggesting that puerarin quenched the fluorescence of CYP1A2 statically instead of dynamically. Likewise, puerarin induced static quenching by forming a complex with CYP2D6.

Figure 2. Stern-Volmer plots for the quenching of CYPs by puerarin at different temperatures. (A) puerarin-CYP1A2; (B) puerarin-CYP2D6.

| System         | T (K) | \( K_{sv} \) (10^4 L⋅mol\(^{-1}\)) | \( K_q \) (10^{12} L⋅mol\(^{-1}\)⋅s\(^{-1}\)) |
|---------------|------|-----------------|-----------------|
| Puerarin-CYP1A2 | 293  | 6.46            | 6.46            |
|                | 303  | 5.98            | 5.98            |
| Puerarin-CYP2D6 | 293  | 5.83            | 5.83            |
|                | 303  | 7.86            | 7.86            |
2.1.3. Binding Constant $K_a$ and Number of Binding Site $n$

When drug molecules independently bind to a suitable site in a protein, there is an equilibrium between interacting and non-interacting molecules [12]:

$$\log\left[\frac{(F_0 - F)}{F}\right] = \log K_a + n \log[Q]$$

(2)

The apparent binding constant $K_a$ and binding site $n$ were calculated by plotting $\log\left[\frac{(F_0 - F)}{F}\right]$ vs. $\log[Q]$ at different temperatures [13–15] (Table 2).

Table 2. Binding constants $K_a$ and numbers of binding sites $n$.

| System          | $T$ (K) | $K_a \ (10^5 \text{ L mol}^{-1})$ | $n$ |
|-----------------|---------|----------------------------------|-----|
| Puerarin-CYP1A2 | 293     | 0.19                             | 0.89|
|                 | 303     | 0.23                             | 0.90|
| Puerarin-CYP2D6 | 293     | 3.39                             | 1.19|
|                 | 303     | 6.56                             | 1.21|

The stoichiometries between puerarin and CYPs were close to 1:1, and $K_a$ increased with rising temperature, which may be attributed to the conformational changes of CYP1A2 and CYP2D6 at various temperatures. Puerarin bound to CYP1A2 more weakly than to CYP2D6, as evidenced by the lower $K_a$ and stoichiometry.

2.1.4. Thermodynamic Parameters and Interaction Force Types

Drugs commonly interact with biomacromolecules via hydrogen bonding, hydrophobic interactions, van der Waals force and electrostatic attraction, etc. The enthalpy change ($\Delta H$) and entropy change ($\Delta S$) during binding can be considered constants at an almost invariable temperature, which can be calculated by the van’t Hoff equation $\log K_a = -\Delta H/RT + \Delta S/R$ and binding equation $\Delta G = \Delta H - T\Delta S$. Thermodynamic parameters were calculated by the binding constants in Table 2 (Table 3).

Table 3. Thermodynamic parameters for the associations of puerarin with CYPs.

| System          | $T$ (K) | $\Delta H \ (\text{kJ mol}^{-1})$ | $\Delta S \ (\text{J mol}^{-1} \cdot \text{K}^{-1})$ | $\Delta G \ (\text{kJ mol}^{-1})$ |
|-----------------|---------|----------------------------------|---------------------------------|---------------------------------|
| Puerarin-CYP1A2 | 293     | 28.78                            | 180.01                          | -23.96                          |
|                 | 303     | 28.78                            | 180.01                          | -25.76                          |
| Puerarin-CYP2D6 | 293     | 95.60                            | 432.17                          | -31.03                          |
|                 | 303     | 95.60                            | 432.17                          | -35.35                          |

Ross et al. classified the interaction forces between drugs and protein by $\Delta H$ and $\Delta S$ into hydrophobic interaction ($\Delta H > 0$, $\Delta S > 0$), van der Waals force ($\Delta H < 0$, $\Delta S < 0$) and electrostatic attraction ($\Delta H < 0$, $\Delta S > 0$) [16].

Since the $\Delta G$ values of the two systems were lower than zero, puerarin interacted with CYPs following thermodynamically spontaneous reactions. Moreover, the positive results of $\Delta H$ and $\Delta S$ indicate puerarin bound to the two CYPs by hydrophobic forces. Puerarin, as a small hydrophobic molecule, intercalated the hydrophobic regions inside CYPs. In addition, hydrogen bonding cannot be ruled out due to the multiple hydroxyl groups of puerarin.
2.2. UV-Vis Spectra

Proteins exhibit UV absorptions owing to Trp (280 nm), Tyr (280 nm) and Phe (257 nm) as well as peptide bonds (225 nm). After adding drugs, the absorptions of protein chromophores are bound to change [17]. As exhibited in Figure 3, CYPs show weak peaks at 257 nm, which can be attributed to the $\pi-\pi^*$ and $n-\pi^*$ transitions of aromatic heterocycle in Phe. With increasing concentration of puerarin, the peaks hypsochromically shifted to 252 nm and became more intense, revealing that puerarin exposed Phe residues inside CYPs by extending the peptide bonds [18].

**Figure 3.** UV-vis spectra of CYPs with different concentrations of puerarin (concentrations of puerarin (1→9): 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and $4 \times 10^{-5}$ mol L$^{-1}$). (A) puerarin-CYP1A2; (B) puerarin-CYP2D6.

2.3. CD Spectra

CD spectra were determined to observe the interactions of puerarin with CYPs and corresponding structural changes (Figure 4). CYPs had negative Cotton effects at 212 nm and 223 nm corresponding to $\alpha$-helix, which were weakened after adding puerarin with slightly varied shapes and positions, suggesting that the secondary structures were altered [19]. With rising puerarin concentration, the $\alpha$-helix contents dropped probably because hydrophobic force and hydrogen bonding with amino acid residues loosened the secondary structures [20].

2.4. Molecular Docking

2.4.1. Molecular Docking of Interactions between Puerarin and CYP1A2

During docking, 50 conformations, one of which had the minimum energy of $-7.57$ kcal·mol$^{-1}$, were selected. Cluster analysis disclosed that the most probable conformation had the energy of $-7.3$ kcal·mol$^{-1}$, and 50% docked conformations were included, inferring that the docked structure was reliable and stable. The docking results were also visualized by Ligplus and Autodock (Figure 5).
Figure 4. CD spectra of puerarin–CYPs in the absence and presence of increasing amount of puerarin (concentrations of puerarin (1→3): 0, 8 × 10⁻⁴ and 9 × 10⁻⁴ mol L⁻¹). (A) puerarin-CYP1A2; (B) puerarin-CYP2D6.

Figure 5. Molecular docking of interactions between puerarin and CYP1A2. (A) Ligplus; (B) Pymol.

By using the location of puerarin-containing protein crystal structure as the active site, a three-dimensional box (40 × 40 × 40) encapsulating the protein active center, a hydrophobic cavity, was constructed, mainly including F226, I314, G316 and A317 residues on α–helix as well as F451 and G459 residues on random coils. Puerarin entered the active center by hydrophobic interactions and hydrogen-bound to R456, I459 and W133.

2.4.2. Molecular Docking of Interactions between Puerarin and CYP2D6

One out of the fifty conformations was of the minimum energy of −7.22 kcal·mol⁻¹. Meanwhile, the binding affinity was predicted as ~μM. The results confirm that the docked structure was reliable and stable. The docking results were also visualized by Ligplus and Autodock (Figure 6).
The location of a two drug molecule-containing protein crystal structure was utilized as the active site. The active pocket mainly consisted of three $\alpha$-helices and random coils that gave rise to hydrophobic grooves, adjoining to which there were THR310, THR309, GLN364, Val370, LEU399, Gly306, Leu448, ALA305, CYS443, Leu302 and phe120, etc. Puerarin entered the active center by hydrophobic interactions and hydrogen-bound to V374 and R101. The molecular docking outcomes were consistent with the spectroscopic results by accurately predicting the interactions between puerarin and CYPs.

3. Experimental

3.1. Apparatus and Reagents

The apparatus used in this study included fluorescence spectrometer (Perkin Elmer LS55, Shelton, WA, USA), UV-Vis spectrometer (Shimadzu UV-2401, Tokyo, Japan), CD spectrometer (JASCO-810, Tokyo, Japan) and pH meter (Leici PHS-25, Shanghai, China).

The reagents included puerarin (standard, National Institutes for Food and Drug Control, Bejing, China), CYP1A2, CYP2D6 ($1 \times 10^{-6}$ mol·L$^{-1}$, BD, stored at $-80$ °C, thawed at room temperature immediately before use), methanol (HPLC grade, Shanghai Lingfeng Chemical Reagent Co., Ltd., Shanghai, China), sodium dihydrogen phosphate, disodium hydrogen phosphate and sodium chloride (analytical grade, Sinopharm Chemical Reagent Co., Ltd., Shanghai, China). Double-distilled water was used throughout the experiments.
3.2. Methods

3.2.1. Preparation of Solutions

(1) Preparation of $1 \times 10^{-3}$ mol·L$^{-1}$ puerarin solution: Puerarin (0.0104 g) was placed in a 25 mL volumetric flask, diluted with HPLC-grade methanol and stored at 4 °C.

(2) Preparation of 0.02 mol·L$^{-1}$ PBS buffer: NaH$_2$PO$_4$ (0.5928 g) and Na$_2$HPO$_4$ (5.8019 g) were placed in a 100 mL volumetric flask and diluted with double-distilled water. The solution (10 mL) was then transferred to another 100 mL volumetric flask, diluted with double-distilled water, pH-adjusted to 7.4, and added 0.5844 g NaCl (0.1 mol·L$^{-1}$) to maintain ionic strength.

3.2.2. Fluorescence Spectroscopy

PBS (2 mL) and 10 µL of CYP1A2 (or 3 µL of CYP2D6) were added in a quartz cuvette, to which were added 10 µL aliquots of $1 \times 10^{-3}$ mol·L$^{-1}$ puerarin solution to the final concentrations of 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and $4 \times 10^{-5}$ mol·L$^{-1}$. Being excited at 280 nm, fluorescence spectra were recorded from 290 to 440 nm at 293 K and 303 K respectively.

3.2.3. UV-Vis Spectroscopy

PBS (2 mL) and 10 µL of CYP1A2 (or 10 µL of CYP2D6) were added in a cuvette, to which were added 10 µL aliquots of $1 \times 10^{-3}$ mol·L$^{-1}$ puerarin solution. UV-vis spectra were measured from 220 to 400 nm.

3.2.4. CD Spectroscopy

Various amounts of puerarin solution and 10 µL of CYP1A2 (or 10 µL of CYP2D6) were added in a quartz cell and diluted with PBS buffer to 1000 µL to the final puerarin concentrations of 0, $8 \times 10^{-4}$ and $9 \times 10^{-4}$ mol·L$^{-1}$. By using the corresponding blank solutions as the backgrounds, CD spectra were measured from 190 to 280 nm. Conformations were calculated using the built-in JASCO-810 software.

3.2.5. Molecular Docking

The binding sites and forces between puerarin and CYPs were predicted by molecular docking. The crystal structures of protein receptors human CYP1A2 (entry: 2HI4) and human CYP2D6 (entry: 3TBG) were obtained from the Protein Data Bank. The structure of puerarin was drawn by ChemOffice 11.0, optimized to the structure with lowest energy, and then processed by Autodock through adding hydrogens, calculating electric charges and docking with the protein receptors.

4. Conclusions

In summary, the interactions between puerarin and two CYPs were studied by fluorescence, UV-Vis and circular dichroism spectroscopies together with molecular docking. Puerarin quenched the fluorescences of CYP1A2 and CYP2D6 statically, and bound to them mainly by hydrophobic force and hydrogen bonding. At the same temperature, puerarin bound to CYP1A2 more weakly than it did to
CYP2D6. Furthermore, puerarin altered the conformations of CYP1A2 and CYP2D6. The findings provide reliable evidence for investigating the interactions between compounds and CYPs as well as for clarifying the structures and functions of CYPs.

Acknowledgments

The authors thank the National Natural Science Foundation of China (No. 81102825) for financial support.

Author Contributions

All authors participated in data collection, analysis, interpretation and commented on the manuscript. All authors agree to be listed and approve the submitted versions.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Ye, X.Y.; Song, H.; Lu, C.Z. Effect of puerarin injection on the mRNA expressions of AT1 and ACE2 in spontaneous hypertension rats. *Chin. J. Integr. Trad. Chin. West. Med.* **2008**, *9*, 824–827.
2. He, Z.G.; Chen, G.; Zhu, H.F.; Ye, L.; Xu, X.Y. Protective effects of puerarin on focal cerebral ischemia-reperfusion injury in rats. *Chin. Pharmacol. Bull.* **2011**, *8*, 1181–1182.
3. Meng, X.H.; Ni, C.; Zhu, L.; Shen, Y.L.; Wang, L.L.; Chen, Y.Y. Puerarin protects against high glucose-induced acute vascular dysfunction: Role of heme oxygenase-1 in rat thoracic aorta. *Vasc. Pharmacol.* **2009**, *3–4*, 110–115.
4. Yan, L.P.; Zhuang, Y.L.; Chan, S.W.; Chen, S.L.; Shi, G.G. Analysis of the mechanisms underlying the endothelium dependent antivaso constriction of puerarin in rat aorta. *Naunyn Schmiedeberg’s Arch. Pharmacol.* **2009**, *6*, 587–597.
5. Dorota, T.S.; Dominique, M.; Julia, K.; Hannah, E.I.; Uwe, F.; Wiebke, A. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. *Eur. J. Endocrinol.* **2010**, *163*, 919–924.
6. Isoherranen, N.; Hachad, H.; Yeung, C.K. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions literature evaluation based on the metabolism and transport drug interaction database. *Chem. Res. Toxicol.* **2009**, *2*, 294–298.
7. Wu, X.F.; Cai, C.X.; Sun, S.G.; Huang, Q.; Ren, G.D.; He, L.; Ma, M.H. Investigation of interaction between riboflavin and riboflavin binding protein by fluorescence spectroscopy. *Spectrosc. Spectr. Anal.* **2012**, *3*, 719–722.
8. Huang, Y.B.; Wang, S.J.; Zi, Y.Q.; Yu, Z.; Gao, X.Y.; Tang, Y.C.; Zhang, D.M. Investigation on the interaction of prulifloxacin with human serum albumin: A spectroscopic analysis. *Chem. Pharm. Bull.* **2010**, *4*, 582–586.
9. Wang, Q.B.; Di, W.; Cheng, X.L.; Zhang, P.H.; Tu, Z.L. Effects of puerarin on the activities of cytochrome P450 enzyme *in vitro*. *Herald Med.* **2008**, *5*, 500–504.
10. Silva, D.; Cortez, C.M.; Silva, C.M.; Missailidis, S. A fluorescent spectroscopy and modeling analysis of anti-heparanase aptamers-serum protein interactions. J. Photochem. Photobiol. B 2013, 127, 68–77.

11. Lakowicz, J.R. Principles of Fluorescence Spectroscopy; Plenum Press: New York, NY, USA, 1983; Chapter 10, pp. 303–339.

12. Olga, A.; Zahra, E.; Hanieh, S.; Jamshidkhan, C. Probing the interaction of human serum albumin with norfloxacin in the presence of high-frequency electromagnetic fields: Fluorescence spectroscopy and circular dichroism investigations. Molecules 2011, 16, 9792–9818.

13. Li, J.F.; Li, J.Z.; Jiao, Y.; Dong, C. Spectroscopic analysis and molecular modeling on the interaction of jatrorrhizine with human serum albumin (HSA). Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2014, 118, 48–54.

14. Xiao, J.B.; Shi, J.; Cao, H.; Wu, S.D.; Ren, F.L.; Xu, M. Analysis of binding interaction between puerarin and bovine serum albumin by multi-spectroscopic method. J. Pharm. Biomed. Anal. 2007, 45, 609–615.

15. Han, X.L.; Mei, P.; Liu, Y.; Xiao, Q.; Jiang, F.L.; Li, R. Binding interaction of quinclorac with bovine serum albumin: A biophysical study. Spectrochim. Acta A 2009, 74, 781–787.

16. Ross, P.D.; Subramanian, S. Thermodynamics of protein association reactions–forces contributing to stability. Biochemistry 1981, 20, 3096–3102.

17. Zhang, F.Y.; Ni, Y.N. A comparison study on the interaction of sunset yellow and β-carotene with bovine serum albumin. Acta Chim. Sin. 2012, 12, 1379–1384.

18. Song, Y.M.; Liu, Z.; Wang, K.J.; Luan, N.N. Interaction of the ternary complexes with anticoagulant property of iron, Copper with human serum albumin. Acta Chim. Sin. 2010, 68, 2191–2198.

19. Nozaki, A.; Kimura, T.; Ito, H.; Hatano, T. Interaction of polyphenolic metabolites with human serum albumin: A circular dichroism study. Chem. Pharm. Bull 2009, 9, 1019–1023.

20. Aurica, V.; Mihaela, H. Bovine and human serum albumin interactions with 3-carboxyphenoxathiin studied by fluorescence and circular dichroism spectroscopy. Molecules 2010, 15, 3905–3919.

Sample Availability: Samples of the compounds are available from the authors.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).